Megestrol Acetate

MEGESTROL ACETATE- megestrol acetate suspension
Bora Pharmaceutical Laboratories Inc.

1 INDICATIONS AND USAGE

Megestrol acetate oral suspension is indicated for the treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS).

Limitations of Use

Therapy with megestrol acetate oral suspension for weight loss should only be insti­tuted after treatable causes of weight loss are sought and addressed. These treatable causes include possible malignancies, systemic infections, gastrointestinal disorders affecting absorption, endocrine disease, renal disease or psychiatric diseases.

Megestrol acetate oral suspension is not intended for prophylactic use to avoid weight loss.

2 DOSAGE AND ADMINISTRATION

2.1 Testing Prior to Megestrol Acetate Oral Suspension Administration

  • Obtain a negative pregnancy test in females of reproductive potential prior to initiating treatment with megestrol acetate oral suspension [see Contraindications ( 4), Warnings and Precautions ( 5.2), Use in Specific Populations ( 8.1, 8.3)].

2.2 Dosing and Administration

  • The recommended adult initial dosage of megestrol acetate oral suspension is 625 mg/day (5 mL/day or one teaspoon daily).
  • Shake the container well before using.
  • This strength (125 mg/mL) is not substitutable with other strengths (e.g., 40 mg/mL). Refer to the prescribing information of the 40 mg/mL product for dosage recommendations for the 40 mg/mL strength.

3 DOSAGE FORMS AND STRENGTHS

Megestrol acetate oral suspension is milky white, lemon flavored, and contains 125 mg per mL.

4 CONTRAINDICATIONS

  • History of hypersensitivity to megestrol acetate or any component of the formulation.
  • Pregnancy [see Warnings and Precautions ( 5.2), Use in Specific Populations ( 8.1, 8.3)].

5 WARNINGS AND PRECAUTIONS

5.1 General

  • Effects on HIV viral replication have not been determined.
  • Use with caution in patients with a history of thromboembolic disease.

5.2 Fetal Toxicity

Based on animal studies, megestrol acetate may cause fetal harm when administered to a pregnant woman. Pregnant rats treated with low doses of megestrol acetate resulted in a reduction in fetal weight and number of live births, and feminization of male fetuses. There are no available human data to assess for any drug associated risks of miscarriage, birth defects, or adverse maternal or fetal outcomes. If this drug is used during pregnancy, or if the patient becomes pregnant while taking (receiving) this drug, advise the patient of the poten­tial hazard to the fetus [see Use in Specific Populations ( 8.1), Nonclinical Toxicology ( 13.1)].

Obtain a pregnancy test in females of reproductive potential prior to initiating treatment with megestrol acetate oral suspension [see Dosage and Administration ( 2.1)]. Advise females of reproductive potential to use effective contraception while taking megestrol acetate oral suspension [see Use in Specific Populations ( 8.3)].

5.3 Adrenal Insufficiency

The glucocorticoid activity of megestrol acetate oral suspension has not been fully evaluated. Clinical cases of overt Cushing’s Syndrome have been reported in association with the chronic use of megestrol acetate. In addition, clinical cases of adrenal insufficiency have been observed in patients receiving or being withdrawn from chronic megestrol acetate therapy in the stressed and non-stressed state. Furthermore, adrenocorticotropin (ACTH) stimulation testing has revealed the frequent occurrence of asymptomatic pituitary-adrenal suppression in patients treated with chronic megestrol acetate therapy. Therefore, the possibility of adrenal insufficiency should be considered in any patient receiving or being withdrawn from chronic megestrol acetate oral suspension therapy who presents with symptoms and/or signs suggestive of hypoadrenalism (e.g., hypotension, nausea, vomiting, dizziness, or weakness) in either the stressed or non-stressed state. Laboratory evaluation for adrenal insufficiency and consideration of replacement or stress doses of a rapidly acting glucocorticoid are strongly recommended in such patients. Failure to recognize inhibition of the hypothalamic-pituitary adrenal axis may result in death. Finally, in patients who are receiving or being withdrawn from chronic megestrol acetate oral suspension therapy, consideration should be given to the use of empiric therapy with stress doses of a rapidly acting glucocorticoid during stress or serious intercurrent illness (e.g., surgery, infection).

5.4 Diabetes

Clinical cases of new onset diabetes mellitus and exacerbation of pre-existing diabetes mellitus have been reported in association with the chronic use of megestrol acetate.

6 ADVERSE REACTIONS

6.1 Serious and Otherwise Important Adverse Reactions

The following serious reactions and otherwise important adverse drug reactions are discussed in greater detail in other sections of the labeling:

  • Hypersensitivity [see Contraindications ( 4)]
  • Thromboembolic Disease [see Warnings and Precautions ( 5.1)]
  • Adrenal Insufficiency [see Warnings and Precautions ( 5.3)]
  • Diabetes [see Warnings and Precautions ( 5.4)]

6.2 Clinical Trial Experience

Because clinical trials are conducted under widely varying conditions, adverse reactions observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of megestrol acetate oral suspension, 125 mg/mL was based on three studies of megestrol acetate oral suspension (40 mg/mL). The adverse reaction profile of these 3 studies are presented below.

Adverse events which occurred in at least 5% of patients in any arm of the two clinical efficacy trials and the open trial for megestrol acetate oral suspension are listed below by treatment group. All patients listed had at least one post baseline visit during the 12 study weeks.

Table 1: Adverse Events

Percentage of Patients Reporting Adverse Events

Trial 1

(N=236)

Trial 2

(N=87)

Open Label

Trial

Placebo

Placebo

Megestrol

Acetate mg/day

0

100

400

800

0

800

1200

No. of Patients

N=34

N=68

N=69

N=65

N=38

N=49

N=176

Diarrhea

15

13

8

15

8

6

10

Impotence

3

4

6

14

0

4

7

Rash

9

9

4

12

3

2

6

Flatulence

9

0

1

9

3

10

6

Hypertension

0

0

0

8

0

0

4

Asthenia

3

2

3

6

8

4

5

Insomnia

0

3

4

6

0

0

1

Nausea

9

4

0

5

3

4

5

Anemia

6

3

3

5

0

0

0

Fever

3

6

4

5

3

2

1

Libido

Decreased

3

4

0

5

0

2

1

Dyspepsia

0

0

3

3

5

4

2

Hyperglycemia

3

0

6

3

0

0

3

Headache

6

10

1

3

3

0

3

Pain

6

0

0

2

5

6

4

Vomiting

9

3

0

2

3

6

4

Pneumonia

6

2

0

2

3

0

1

Urinary Frequency

0

0

1

2

5

2

1

Adverse events which occurred in 1% to 3% of all patients enrolled in the two clinical efficacy trials with at least one follow-up visit during the first 12 weeks of the study are listed below by body system. Adverse events occurring less than 1% are not included. There were no significant differences between incidence of these events in patients treated with megestrol acetate and patients treated with placebo.

Body as a Whole – abdominal pain, chest pain, infection, moniliasis and sarcoma

Cardiovascular System – cardiomyopathy and palpitation

Digestive System – constipation, dry mouth, hepatomegaly, increased salivation and oral moniliasis

Hemic and Lymphatic System – leukopenia

Metabolic and Nutritional – LDH increased, edema and peripheral edema

Nervous System – paresthesia, confusion, convulsion, depression, neuropathy, hypesthesia and abnormal thinking

Respiratory System – dyspnea, cough, pharyngitis and lung disorder

Skin and Appendages – alopecia, herpes, pruritus, vesiculobullous rash, sweating and skin disorder

Special Senses – amblyopia

Urogenital System – albuminuria, urinary incontinence, urinary tract infection and gynecomastia.

Page 1 of 4 1 2 3 4

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2024. All Rights Reserved.